Drugs / Mogamulizumab
Mogamulizumab
also known as
KW-0761 · AMG 761 · KM-8761 · Mogamulizumab (genetical recombination) · Mogamulizumab-Kpkc · Mogamulizumab: KW-0761 · Poteligeo
Monoclonal antibody targets CCR4
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Poteligeo | — | 2018-11-22 | europa.eu ↗ |
| Approved | US (FDA) | POTELIGEO | — | 2018-08-08 | fda.gov ↗ |
Trials 35 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06235281 | Jan 2024 → Sep 2026 | mycosis fungoides | H. Lee Moffitt Cancer Center and Research Institute | Suspended | No outcome recorded |
| Phase 112 trials | ||||||
| Phase 1 | NCT05414500 | May 2023 → Jun 2027 | mycosis fungoides | University of Alabama at Birmingham | Suspended | No outcome recorded |
| Phase 1 | NCT04848064 | May 2022 → Oct 2026 expected | adult T-cell leukemia/lymphoma, primary cutaneous T-cell lymphoma | John Reneau | Recruiting | No outcome recorded |
| Phase 1 | NCT04185220 | Feb → Nov 2020 | Sezary syndrome, adult T-cell leukemia/lymphoma, mycosis fungoides | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT02867007 | Aug 2016 → Dec 2019 | carcinoma | Kyowa Kirin, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02946671 | Mar 2016 → Mar 2020 | esophageal cancer, gastric cancer, kidney cancer, lung cancer +1 | Osaka University | Completed | No outcome recorded |
| Phase 1 | NCT02476123 | Jun 2015 → Feb 2018 | cancer | Kyowa Kirin, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02444793 | May 2015 → Sep 2017 | — | Pfizer | Terminated | No outcome recorded |
| Phase 1 | NCT02358473 | Jan 2015 → Dec 2016 | non-small cell lung carcinoma | Kyowa Kirin, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02301130 | Nov 2014 → Dec 2017 | cancer | Kyowa Kirin, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01929486 | Feb 2013 → Jun 2016 | cancer | Aichi Medical University | Unknown | No outcome recorded |
| Phase 1 | NCT01514981 | Dec 2011 → Jan 2014 | asthma | Amgen | Terminated | No outcome recorded |
| Phase 1 | NCT00355472 | Feb 2007 → Oct 2008 | adult T-cell leukemia/lymphoma, peripheral T-cell lymphoma, not otherwise specified | Kyowa Kirin, Inc. | Completed | No outcome recorded |
| Phase 1/26 trials | ||||||
| Phase 1/2 | NCT04676087 | Apr 2021 → Oct 2023 | Sezary syndrome, mycosis fungoides | Emory University | Terminated | No outcome recorded |
| Phase 1/2 | NCT04541017 | Apr 2021 → Oct 2024 | Sezary syndrome, mycosis fungoides | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 1/2 | NCT03309878 | Oct 2018 → Jan 2021 | high grade B-cell lymphoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/2 | NCT02705105 | Feb 2016 → Aug 2018 | hepatocellular carcinoma | Kyowa Kirin, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT02281409 | Oct 2014 → Feb 2020 | cancer, metastatic neoplasm | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1/2 | NCT00888927 | May 2009 → Sep 2012 | peripheral T-cell lymphoma, not otherwise specified | Kyowa Kirin, Inc. | Completed | No outcome recorded |
| Phase 213 trials | ||||||
| Phase 2 | NCT06698003 | Nov 2024 → Nov 2029 expected | T-cell and NK-cell neoplasm, adult T-cell leukemia/lymphoma | Memorial Sloan Kettering Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT05996185 | Oct 2024 → Nov 2026 expected | T-cell non-Hodgkin lymphoma | Yale University | Recruiting | No outcome recorded |
| Phase 2 | NCT05956041 | Dec 2023 → Dec 2026 expected | mycosis fungoides and variants | University of Michigan Rogel Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT04128072 | Mar 2023 → Oct 2026 expected | primary cutaneous T-cell lymphoma | European Organisation for Research and Treatment of Cancer - EORTC | Recruiting | No outcome recorded |
| Phase 2 | NCT04930653 | Oct 2022 → Jun 2028 expected | Sezary syndrome, folliculotropic mycosis fungoides | City of Hope Medical Center | Recruiting | No outcome recorded |
| Phase 2 | NCT04745234 | Aug 2021 → May 2025 | primary cutaneous T-cell lymphoma | Kyowa Kirin, Inc. | Unknown | No outcome recorded |
| Phase 2 | NCT04256018 | Mar 2020 → Dec 2026 expected | Sezary syndrome, mycosis fungoides | Stanford University | Recruiting | No outcome recorded |
| Phase 2 | NCT01626664 | Jun 2012 → Aug 2015 | adult T-cell leukemia/lymphoma | Kyowa Kirin, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01611142 | Apr 2012 → May 2015 | peripheral T-cell lymphoma, not otherwise specified | Kyowa Kirin, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01192984 | Sep 2010 → May 2012 | mature T-cell and NK-cell non-Hodgkin lymphoma | Kyowa Kirin, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01226472 | Aug 2010 → Sep 2012 | peripheral T-cell lymphoma, not otherwise specified, primary cutaneous T-cell lymphoma | Kyowa Kirin, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01173887 | Jul 2010 → Apr 2012 | adult T-cell leukemia/lymphoma | Kyowa Kirin, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00920790 | Jun 2009 → Jul 2010 | adult T-cell leukemia/lymphoma | Kyowa Kirin, Inc. | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT03191526 | May 2017 → Jun 2019 | tropical spastic paraparesis | Kyowa Kirin, Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT01728805 | Nov 2012 → Mar 2017 | primary cutaneous T-cell lymphoma | Kyowa Kirin, Inc. | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT06285370 | May 2023 → Aug 2025 overdue | primary cutaneous T-cell lymphoma | Kyowa Kirin Co., Ltd. | Active not recruiting | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07529405 Comparator | Jul 2026 → Dec 2030 expected | mycosis fungoides | Virogen Biotechnology Inc. | Not yet recruiting | No outcome recorded |
Evidence & citations 12 cited values
Every value below carries the sentence it was read from. 38 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | mogamulizumab | “Mogamulizumab (KW-0761) is a defucosylated humanized anti-CCR4 antibody engineered to exert potent antibody-dependent cellular cytotoxicity.” PMID 24616310 ↗ Mar 201424“Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma.” PMID 25605368 ↗ Jan 2015 |
| Known as | AMG 761 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01514981 ↗ |
| Known as | KM-8761 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1743041 ↗ |
| Known as | KW-0761 | “Mogamulizumab (KW-0761) is a defucosylated humanized anti-CCR4 antibody engineered to exert potent antibody-dependent cellular cytotoxicity.” PMID 24616310 ↗ Mar 2014 |
| Known as | Mogamulizumab (genetical recombination) | ChEMBL registry synonym — accepted as the source's own label CHEMBL1743041 ↗ |
| Known as | Mogamulizumab-Kpkc | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06235281 ↗ |
| Known as | Mogamulizumab: KW-0761 | “Mogamulizumab: KW-0761” NCT02867007 ↗ |
| Known as | Poteligeo | ChEMBL registry synonym — accepted as the source's own label CHEMBL1743041 ↗ |
| Action | Deplete | “with enhanced antibody dependent cellular cytotoxicity (ADCC)” NCT01611142 ↗ |
| Modality | Monoclonal antibody | “a defucosylated, humanized, anti-CC chemokine receptor 4 monoclonal antibody” PMID 25605368 ↗ Jan 2015 |
| Route | Intravenous | “IV administration at 4 escalating dose levels.” NCT00355472 ↗ |
| Target | CCR4 | “anti-CCR4 antibody” PMID 25605368 ↗ Jan 2015 |